Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 74

Similar articles for PubMed (Select 22882484)

1.

Tyrosine kinase inhibitor special issue.

Thamm DH.

Vet Comp Oncol. 2012 Sep;10(3):161-2. doi: 10.1111/j.1476-5829.2012.00339.x. No abstract available.

PMID:
22882484
2.

Opportunities and challenges in the development of kinase inhibitor therapy for cancer.

Sawyers CL.

Genes Dev. 2003 Dec 15;17(24):2998-3010. Review. No abstract available.

3.

[Tyrosine kinase inhibitors. An approach to pathogenesis-oriented tumor therapy].

Alves F, Hiddemann W.

Internist (Berl). 1997 Nov;38(11):1074-82. Review. German. No abstract available.

PMID:
9453957
4.

Multitarget tyrosine kinase inhibition: [and the winner is...].

Verweij J, de Jonge M.

J Clin Oncol. 2007 Jun 10;25(17):2340-2. Review. No abstract available.

PMID:
17557945
5.

Pazopanib: a novel multitargeted tyrosine kinase inhibitor.

Sonpavde G, Hutson TE.

Curr Oncol Rep. 2007 Mar;9(2):115-9. Review.

PMID:
17288876
6.

Targeting cancers with tyrosine kinase inhibitors: lessons learned from chronic myeloid leukaemia.

Mughal TI, Goldman JM.

Clin Med. 2006 Nov-Dec;6(6):526-8. No abstract available.

PMID:
17228548
7.

[Protein tyrosine kinase inhibitors in cancer therapy].

Boutayeb S, Zakkouri FZ, Aitelhaj M, Mesmoudi M, Boutayeb A, Boutayeb W, Mrabti H, Errihani H.

Pathol Biol (Paris). 2012 Aug;60(4):229-33. doi: 10.1016/j.patbio.2012.05.007. Epub 2012 Jun 26. Review. French.

PMID:
22743095
8.

[Tyrosine kinases as targets of cancer therapy: from disbelief to Lazarus responses].

Joensuu H.

Duodecim. 2012;128(21):2261-8. Review. Finnish.

PMID:
23210289
9.

Current topics and the clinical effects of target-based antineoplastic agents.

Maehara Y, Egashira A, Kakeji Y.

Int J Clin Oncol. 2006 Jun;11(3):164-6. No abstract available.

PMID:
16850121
10.

Tyrosine kinase inhibitors: from rational design to clinical trials.

Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, O'Reilly T, Wood J, Zimmermann J.

Med Res Rev. 2001 Nov;21(6):499-512. Review.

PMID:
11607931
11.

[Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals].

Grimm CF, Blum HE, Geissler M.

Dtsch Med Wochenschr. 2005 May 27;130(21):1318-22. Review. German. No abstract available.

PMID:
15902620
12.

Tyrosine kinases as targets for cancer therapy.

Levitzki A.

Eur J Cancer. 2002 Sep;38 Suppl 5:S11-8. Review.

PMID:
12528768
13.

Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents.

Laird AD, Cherrington JM.

Expert Opin Investig Drugs. 2003 Jan;12(1):51-64. Review.

PMID:
12517254
14.

Rational therapeutic intervention in cancer: kinases as drug targets.

Sawyers CL.

Curr Opin Genet Dev. 2002 Feb;12(1):111-5. Review.

PMID:
11790564
15.

Tyrosine kinases as targets in cancer therapy - successes and failures.

Traxler P.

Expert Opin Ther Targets. 2003 Apr;7(2):215-34. Review.

PMID:
12667099
16.

Role of protein tyrosine kinase inhibitors in cancer therapeutics.

Bhise SB, Nalawade AD, Wadhawa H.

Indian J Biochem Biophys. 2004 Dec;41(6):273-80. Review.

PMID:
22900354
17.

Tyrosine kinase inhibitor STI-571: the new wonder drug of cancer therapy.

Haydon RC, Zhou L, He TC.

Cancer Biol Ther. 2004 Apr;3(4):393-4. Epub 2004 Apr 12. No abstract available.

18.

Treating cancer's kinase 'addiction'.

Baselga J, Arribas J.

Nat Med. 2004 Aug;10(8):786-7. No abstract available.

PMID:
15286778
19.

Bad patients meet good drugs.

Lacal JC.

Clin Transl Oncol. 2006 Apr;8(4):225-7. No abstract available.

PMID:
16648096
20.

[Anti-angiogenic agents in cancerology: myth or reality?].

Armand JP.

Ann Pharm Fr. 2005 Jan;63(1):25-7. Review. French. No abstract available.

PMID:
15803097
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk